Gene Therapy News and Resources for Healthcare

Top Payer Strategies Around Payment Models for Advanced Therapies

July 27, 2022 - In early 2020, fifteen healthcare leaders—spanning a wide range of backgrounds from government to industry to academia—converged for a little over a day to discuss a single, pressing issue that affected each of their fields: how to establish payment models for advanced therapies. Blue Cross Blue Shield Association (BCBSA) and the Aspen Institute convened this diverse...

How A Rare Condition Can Fuel Medicaid Spending, Utilization

November 16, 2021 by Kelsey Waddill

Medicaid spending on sickle cell disease treatment and patient outcomes among beneficiaries with sickle cell disease reveal gaps in health equity and opportunities for improving care for...

Aetna Will Offer Some Gene Therapies As Standard Medical Benefit

November 01, 2021 by Kelsey Waddill

Aetna members will have better access to gene therapies in 2022, the payer announced. “Gene therapy is poised for significant growth in the coming years, and the promise of durable improvement...

3 Ways to Cut Payer, Employer Gene Therapy Healthcare Spending

March 10, 2021 by Kelsey Waddill

As gene therapies become more widespread, payers continue to rely on proven strategies to reduce gene therapy healthcare spending, CVS Health’s Health Trends Report 2021 explained. The report...

2021 Payer Strategies Build on Telehealth, Gene Therapy Lessons

January 22, 2021 by Kelsey Waddill

In 2021, payers will expand upon lessons learned about telehealth and gene therapy in 2020 as they implement their strategies in the new year. Listen to the full podcast to hear more details. And...

CMS Proposed Rule Redefines Payer Value-Based Payment Negotiations

June 18, 2020 by Kelsey Waddill

CMS has proposed a rule that allows payers to adopt new value-based payment models for gene therapies. “CMS’s rules for ensuring that Medicaid receives the lowest price available for...

Analysis of Claims Data Shows 200% Spike in Alzheimer’s, Dementia

March 05, 2020 by Samantha McGrail

The number of commercially insured Americans age 30 to 64 diagnosed with early-onset dementia or Alzheimer’s disease increased by 200 percent from 2013 to 2017, according to an assessment of...